Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.
First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Eur J Clin Invest. 2023 Mar;53(3):e13900. doi: 10.1111/eci.13900. Epub 2022 Nov 17.
BACKGROUND: Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) levels have been suggested as novel atherosclerotic biomarker. PCSK9 plays important roles in the pathogenesis of atherosclerosis by regulating the degradation of low-density lipoprotein receptor as well as different inflammatory pathways. Considering the important prognostic role of arterial stiffness in cardiovascular disease (CVD), the aim of the study is to investigate the correlation between PCSK9 levels and arterial stiffness in a cohort of diabetic patients, without previous CV events. METHODS: This cross-sectional analysis enrolled 401 Caucasian patients with type II diabetes mellitus (T2DM). PCSK9 levels were measured by ELISA test, arterial stiffness was estimated by measuring carotid-femoral pulse wave velocity (PWV). RESULTS: Patients were divided in three tertiles according to increasing value of PCSK9. From the I to the III tertiles, there was a significant increase in high sensitivity C-reactive protein (hs-CRP), fibrinogen and white blood cells (WBC) and a reduction in estimated glomerular filtration rate (e-GFR). Patients with higher levels of PCSK9 presented increased systolic, diastolic blood pressure, pulse pressure and PWV. PWV was significantly and directly correlated with PCSK9, fibrinogen, age, BMI and PP, and indirectly correlated with diet, lifestyle and e-GFR. Serum PCSK9 was the major predictor of PWV, justifying a 16.9% of its variation. CONCLUSION: Our study demonstrates a close association between circulating PCSK9 levels and PWV in T2DM subjects without previous CV events even after adjusting for well-known CV risk factor and pharmacological medications. Serum PCSK9 could be a useful biomarker for CV risk stratification in diabetic subjects.
背景:前蛋白转化酶枯草溶菌素 9(PCSK9)水平被认为是一种新型的动脉粥样硬化生物标志物。PCSK9 通过调节低密度脂蛋白受体的降解以及不同的炎症途径,在动脉粥样硬化的发病机制中发挥重要作用。考虑到动脉僵硬度在心血管疾病(CVD)中的重要预后作用,本研究旨在探讨在无先前心血管事件的 2 型糖尿病患者队列中,PCSK9 水平与动脉僵硬度之间的相关性。
方法:本横断面分析纳入了 401 名白种人 2 型糖尿病患者。通过 ELISA 试验测量 PCSK9 水平,通过测量颈股脉搏波速度(PWV)来评估动脉僵硬度。
结果:根据 PCSK9 值的增加,患者被分为三个三分位组。从第 1 到第 3 三分位,高敏 C 反应蛋白(hs-CRP)、纤维蛋白原和白细胞(WBC)显著增加,估算肾小球滤过率(e-GFR)降低。PCSK9 水平较高的患者收缩压、舒张压、脉压和 PWV 均升高。PWV 与 PCSK9、纤维蛋白原、年龄、BMI 和 PP 呈显著正相关,与饮食、生活方式和 e-GFR 呈间接相关。血清 PCSK9 是 PWV 的主要预测因子,可解释其 16.9%的变异性。
结论:本研究表明,在无先前心血管事件的 2 型糖尿病患者中,循环 PCSK9 水平与 PWV 密切相关,即使在调整了已知的心血管危险因素和药物治疗后也是如此。血清 PCSK9 可能是糖尿病患者心血管风险分层的有用生物标志物。
Nutr Metab Cardiovasc Dis. 2019-4-24
Diabetes Metab Res Rev. 2015-10-28
Lipids Health Dis. 2018-1-17
Diabetes Obes Metab. 2018-1-14
Diabetol Metab Syndr. 2023-12-20
Int J Mol Sci. 2023-1-19